By Capping Out-Of-Pocket Price, Eli Lilly Could Transform Insulin Market

  • 📰 ForbesTech
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 59%

Россия Новости Новости

Россия Последние новости,Россия Последние новости

Eli Lilly To Lower Insulin Prices And Introduce A $35 Out-Of-Pocket Monthly Cap For Commercially Insured And Uninsured Diabetics

which Eli Lilly posted will take effect in the fourth quarter for Humalog and Humulin, its two biggest-selling insulin products. Apart from this move, the manufacturer stated that as of May 1st it will reduce the list price of an unbranded insulin it sells from $82 to $25 a vial.

It will be interesting to observe whether other insulin-manufacturing companies will follow suit with price reductions. They may have to, as otherwise they could lose a considerable amount of their market share. In addition, it will be intriguing to note how payers and PBMs respond.

Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше:

 /  🏆 318. in RU
 

Спасибо за ваш комментарий. Ваш комментарий будет опубликован после проверки

Россия Последние новости, Россия Последние новости